Fund Allocation and Utilization - Global offering net proceeds amounted to approximately HKD 392.7 million (equivalent to approximately RMB 356.8 million)[1] - 42% of the net proceeds (HKD 164.9 million) allocated for CU-20401 R&D personnel costs and ongoing R&D activities[1] - 11% of the net proceeds (HKD 43.2 million) allocated for CU-40102 and CU-10201 R&D personnel costs and ongoing R&D activities[1] - 10% of the net proceeds (HKD 39.3 million) allocated for technology and business development for pipeline expansion[1] - 5% of the net proceeds (HKD 19.6 million) allocated for working capital and general corporate purposes[1] - As of December 31, 2023, HKD 130.2 million of the net proceeds had been utilized, with HKD 262.5 million remaining unused[1] Equity Incentive Plan - 30,402,446 shares were available for issuance under the post-IPO equity incentive plan, representing 9.98% of the company's issued shares[2] - The post-IPO equity incentive plan allows for the granting of options or share awards with a minimum holding period of 12 months from the grant date[2]
科笛-B(02487) - 2024 - 年度业绩